Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 30, 2007

Astellas Licenses Regeneron’s mAb Technology in a Deal Potentially Worth $120M

  • Astellas Pharma will utilize Regeneron Pharmaceuticals’ technology in its research to discover human mAb product candidates.

    Under the terms of the nonexclusive license deal for VelocImmune, Astellas will pay $20 million upfront and will make up to five additional annual payments of $20 million per year. It retains the ability to terminate the agreement after making the first three payments. Upon commercialization of any antibody products discovered utilizing VelocImmune, Astellas will pay a mid-to-single digit royalty on sales.

    Regeneron says its VelocImmune technology offers the potential to increase the speed and efficiency of discovering fully human therapeutic mAbs. The VelocImmune platform generates mAbs to address clinically relevant targets of therapeutic interest.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »